Metastatic Pancreatic Cancer Responds to Daraxonrasib Combo Therapy

European Organisation for Research and Treatment of Cancer

Barcelona, Spain: Daraxonrasib combined with chemotherapy caused substantial tumour shrinkage in patients with pancreatic cancer that had spread to other parts of the body, according to new results from a phase I/II clinical trial.

In a presentation of the results from the RMC-GI-102 trial on Friday at the 38th EORTC-NCI-AACR [1] Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Spain, the principal investigator said the drug combination not only shrank tumours but also showed encouraging prolonged disease control when used in patients who had not previously received treatment for metastatic disease.

Dr Wungki Park, a gastrointestinal medical oncologist at Memorial Sloan Kettering Cancer Center, New York City, USA, said: "Pancreatic cancer remains one of the most challenging cancers to treat, particularly because more than half of patients present with disease that has already spread to other organs. We need effective treatments that can achieve deep responses and prolong disease control to curb this aggressively devastating disease. For most patients with previously untreated metastatic pancreatic cancer, chemotherapy remains the foundation of treatment. Although chemotherapy can shrink tumours by a modest amount and help some patients, the cancer frequently develops resistance and begins growing again."

Most patients with metastatic pancreatic cancer treated with standard chemotherapy survive for between eight to eleven months, and only three per cent are alive five years after diagnosis [2]. Tumour shrinkage is seen in only 23%-42% of patients treated with chemotherapy, and most tumours start to grow again after five to six months.

"What is particularly encouraging about these new and updated results I am presenting today is that we are beginning to see not only a higher percentage of tumour response rates, but also deeper responses and a near doubling in the duration of disease control, which may eventually translate into longer survival," he said.

As of 28 September 2026, 61 patients had received the drug combination. The median (average) follow-up was 18.3 months, with a range of 13.1 to 23.7 months. Tumours shrank or disappeared in 60.7% of patients (the objective response rate). This included complete responses in 8.2% of patients in whom tumours were no longer detectable, and tumours stopped growing in 90.2% of patients (the disease control rate). The median time before tumours returned or started growing again was 12.8 months (the median progression-free survival).

"This represents a potentially transformative advance in first-line treatment for patients with metastatic pancreatic cancer, already outpacing the high end for the historical overall survival of 8.5-11.1 months with conventional chemotherapy," said Dr Park.

More than 90% of pancreatic cancers have a mutation in the RAS gene that drives the cancer's growth. RAS acts like a molecular switch that tells cells when to grow. In pancreatic cancer the switch becomes stuck in the 'on' state, continuously sending signals that drive cancer cells to divide and grow. This makes the RAS mutation a critical target for new treatments but, until recently, targeting RAS successfully was not possible.

Daraxonrasib is designed to stop an active protein called RAS (ON), and interfere with the signals that pancreatic cancer cells depend on for survival. RMC-GI-102 is a phase I/II study that combines daraxonrasib with standard chemotherapy as a first-line treatment to test this hypothesis.

Patients in the trial received 200 mg of daraxonrasib, taken orally once a day, and two chemotherapy drugs, gemcitabine and nab-paclitaxel, given by intravenous injection on days 1 and 15 of each treatment cycle. Gemcitabine was given at 1,000 milligrams per square metre of body surface area (1,000 mg/m2) and nab-paclitaxel at 125 mg/m2.

"By combining daraxonrasib with chemotherapy, we are seeing remarkably deep tumour responses in a substantial proportion of patients, together with durable disease control, with a median progression-free survival exceeding one year," said Dr Park.

The most common, adverse side effects included rash, diarrhoea, fatigue and those known to be associated with chemotherapy such as cytopenia (a reduction in some blood cells), which were managed adequately with standard medical interventions. Discontinuation of treatment due to daraxonrasib-related side effects was infrequent, occurring in five per cent of patients.

Dr Park said: "These more mature results are particularly exciting because we are now seeing not only substantial tumour shrinkages, including complete responses, but also durable disease control, with median progression-free survival exceeding one year, nearly doubling that reported historically with standard chemotherapy. Importantly, the 12-month overall survival rate of 76.6% provides further insight into the sustained clinical benefit. Together, these findings represent a potentially transformative advance in our pursuit of more effective first-line treatments for metastatic pancreatic cancer.

"However, this is an early-phase study, and the results must be interpreted carefully because patients were not compared with patients receiving chemotherapy alone. The next step is to determine whether these remarkable early findings translate into improved outcomes in a large randomised clinical trial. This is precisely the question being addressed by the global Phase III RASolute-303 trial, which is evaluating daraxonrasib both as a standalone treatment and in combination with gemcitabine and nab-paclitaxel, compared with chemotherapy alone."

Dr Park is the principal investigator of RASolute-303 . "The results from RMC-GI-102 provide important clinical evidence supporting the treatment strategy now being evaluated in the RASolute-303 study," he said.

Professor Elena Garralda, chair of the EORTC-NCI-AACR Symposium (ENA) and co-director of the Vall d'Hebron Institute of Oncology's clinical research programme, was not involved with the study. She commented: "Pancreatic cancer is one of the most difficult cancers to treat successfully, particularly if it has started to spread to other parts of the body. These results are exciting because they show the combined treatment could potentially significantly improve patients' overall survival, as well as the time before tumours start to grow again.

"This study is one of several being presented at ENA today that demonstrate that it is now possible to target the RAS mutations driving cancer growth. Importantly, it shows that RAS-targeted therapies can be combined with existing treatments to achieve potentially more durable clinical benefits for patients, and that it can be given to patients immediately as first-line therapy, enabling the treatment to start at an earlier stage in the course of advanced disease."

RAS mutations drive other cancers too, including certain lung, bowel, biliary tract, appendiceal and gynaecological cancers. Clinical trials for each of these diseases would be needed to see if the combination of daraxonrasib and chemotherapy could improve patient outcomes.

/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.